Education
About Us
Working with TipRanks
Follow Us
Zentalis Pharmaceuticals (ZNTL)
NASDAQ:ZNTL
ZNTL Stock Chart & Stats
$1.41
-$0.17(-5.69%)
At close: 4:00 PM EST
$1.41
-$0.17(-5.69%)
Day’s Range― - ―
52-Week Range$1.01 - $3.95
Previous CloseN/A
Volume750.15K
Average Volume (3M)716.92K
Market Cap
$172.68M
Enterprise Value$168.15M
Total Cash (Recent Filing)$280.70M
Total Debt (Recent Filing)$36.71M
Price to Earnings (P/E)―
Beta2.57
Next Earnings
Mar 04, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding72,250,780
10 Day Avg. Volume819,524
30 Day Avg. Volume716,917
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.64
Price to Sales (P/S)3.19
P/FCF Ratio-1.26
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue6.26
Enterprise Value/Gross Profit6.32
Enterprise Value/Ebitda-1.16
Forecast
1Y Price Target
$7.00Price Target Upside396.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker‑driven ExpansionA focused Cyclin E1 biomarker strategy plus planned mechanism‑based combinations offers a credible route to broaden azenosertib's use into additional tumor types and treatment settings.
Clinical DifferentiationReproducible efficacy versus standard chemotherapy positions azenosertib as a potentially differentiated therapy in Cyclin E1‑driven ovarian cancer, which could drive investor interest on positive data.
Enrollment MilestoneCompletion of enrollment in DENALI Part 2a provides a clear path to a pivotal efficacy readout for azenosertib in Cyclin E1‑positive platinum‑resistant ovarian cancer, supporting upside if results meet expectations.
Bears Say
Binary Trial Outcome RiskHeavy reliance on DENALI trial outcomes introduces a binary clinical risk where missed efficacy or durability thresholds could sharply reduce upside and investor confidence.
Market Sensitivity To MilestonesStock valuation is likely to be highly sensitive to trial and approval milestones, increasing the risk of significant share price volatility if key events disappoint.
Regulatory DependencyReliance on FDA review for any accelerated approval creates material regulatory dependency that could delay market access or prevent approval even with seemingly positive trial results.
Zentalis Pharmaceuticals News
ZNTL FAQ
What was Zentalis Pharmaceuticals’s price range in the past 12 months?
Zentalis Pharmaceuticals lowest stock price was $1.01 and its highest was $3.95 in the past 12 months.
What is Zentalis Pharmaceuticals’s market cap?
Zentalis Pharmaceuticals’s market cap is $172.68M.
When is Zentalis Pharmaceuticals’s upcoming earnings report date?
Zentalis Pharmaceuticals’s upcoming earnings report date is Mar 04, 2026 which is in 14 days.
How were Zentalis Pharmaceuticals’s earnings last quarter?
Zentalis Pharmaceuticals released its earnings results on Nov 10, 2025. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.528 by $0.158.
Is Zentalis Pharmaceuticals overvalued?
According to Wall Street analysts Zentalis Pharmaceuticals’s price is currently Undervalued.
Does Zentalis Pharmaceuticals pay dividends?
Zentalis Pharmaceuticals does not currently pay dividends.
What is Zentalis Pharmaceuticals’s EPS estimate?
Zentalis Pharmaceuticals’s EPS estimate is -0.43.
How many shares outstanding does Zentalis Pharmaceuticals have?
Zentalis Pharmaceuticals has 72,250,780 shares outstanding.
What happened to Zentalis Pharmaceuticals’s price movement after its last earnings report?
Zentalis Pharmaceuticals reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.528. Following the earnings report the stock price went up 6.061%.
Which hedge fund is a major shareholder of Zentalis Pharmaceuticals?
Currently, no hedge funds are holding shares in ZNTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zentalis Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (396.45% Upside)
$7.00 (396.45% Upside)
Hedge Fund Trend
Increased
By 51.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.33%
12-Months-Change
Fundamentals
Return on Equity
-49.18%
Trailing 12-Months
Asset Growth
-28.47%
Trailing 12-Months
Company Description
Zentalis Pharmaceuticals
Zentalis Pharmaceuticals (ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The company operates in the biotechnology sector, leveraging its expertise in medicinal chemistry and translational science to develop drug candidates aimed at improving patient outcomes in oncology. Zentalis' core products include a pipeline of proprietary agents designed to address unmet medical needs in cancer treatment.
ZNTL Stock 12 Month Forecast
Average Price Target
$7.00
▲(396.45% Upside)
Technical Analysis
MacroGenics
―
VistaGen Therapeutics
―
Anixa Biosciences
―
Spero Therapeutics
―
Surrozen
―
Ownership Overview
31.76% Insiders
5.96% Mutual Funds
<0.01% Other Institutional Investors
58.32% Public Companies and
Individual Investors